BioCentury | Jan 7, 2013
Finance

Highlights of weekly biotech stock moves

...develop and commercialize any candidates worldwide except in China, where Guangzhou BeBetter will have rights. Proteologics Inc....
...to NIS0.98 Christmas week after Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) said it is returning to Proteologics...
BioCentury | Jan 7, 2013
Company News

Teva, Proteologics deal

...it will return rights to three preclinical compounds in development for cancer and inflammation to Proteologics...
...decision to return rights to the three compounds to Proteologics. Teva declined to disclose details. Proteologics...
...programs under a 2005 deal with Proteologics to discover cancer compounds that target ubiquitin ligases. Proteologics...
BioCentury | Dec 28, 2012
Company News

Teva returning preclinical compounds to Proteologics

...it will return rights to three preclinical compounds in development for cancer and inflammation to Proteologics Inc....
...decision to return rights to the three compounds to Proteologics. Teva declined to disclose details. Proteologics...
...programs under a 2005 deal with Proteologics to discover cancer compounds that target ubiquitin ligases. Proteologics...
BioCentury | Dec 10, 2012
Company News

Proteologics board of directors update

Proteologics Inc. (Tel Aviv:PRTL), Orangeburg, N.Y. Business: Infectious, Cancer, Proteomics Appointed: Efri Argaman as chairman WIR Staff cancer Infectious...
BioCentury | Dec 3, 2012
Company News

Proteologics, Teva, XTL deal

...XTL said it acquired 4.6 million (31.35%) of biopharmaceuticals company Proteologics from Teva at NIS1.41 per...
...NIS6.5 million ($1.7 million). XTL said the shares represent the entirety of Teva's stake in Proteologics...
...Proteologics and GlaxoSmithKline plc (LSE:GSK; NYSE:GSK, London, U.K.) partnered to discover drugs to treat cancer. Proteologics Inc....
BioCentury | Jul 21, 2011
Targets & Mechanisms

Celgene skips SKP2

...compounds with improved potency, he noted. In February 2010, GSK entered into a collaboration with Proteologics Inc....
...LSE:GSK; NYSE:GSK), London, U.K. Millennium Pharmaceuticals Inc. (NASDAQ:MLNM), Cambridge, Mass. Progenra Inc. , Malvern, Pa. Proteologics Inc....
BioCentury | Apr 19, 2010
Strategy

Finding cancer flexibility

...for development to treat solid tumors Undisclosed upfront payment, equity investment, milestones, royalties Sep 2008 Proteologics Inc....
BioCentury | Sep 22, 2008
Company News

Proteologics, Teva deal

...programs under a 2005 deal with Proteologics to discover cancer compounds that target ubiquitin ligases. Proteologics...
...also granted Teva an exclusive, worldwide license to an undisclosed discovery program to treat cancer. Proteologics...
...and commercialization. Proteologics is eligible for undisclosed milestones and royalties (see BioCentury, March 9, 2005). Proteologics Inc....
BioCentury | Dec 4, 2006
Company News

Proteologics, Teva deal

...payment was triggered by Proteologics' identification and validation of a ubiquitin ligase as a target. Proteologics Inc....
BioCentury | May 9, 2005
Company News

Proteologics, Teva Pharmaceuticals Industries Ltd. deal

...exchange for milestones and royalties if. Also, TEVA made an undisclosed equity investment in Proteologics. Proteologics Inc....
Items per page:
1 - 10 of 12
BioCentury | Jan 7, 2013
Finance

Highlights of weekly biotech stock moves

...develop and commercialize any candidates worldwide except in China, where Guangzhou BeBetter will have rights. Proteologics Inc....
...to NIS0.98 Christmas week after Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) said it is returning to Proteologics...
BioCentury | Jan 7, 2013
Company News

Teva, Proteologics deal

...it will return rights to three preclinical compounds in development for cancer and inflammation to Proteologics...
...decision to return rights to the three compounds to Proteologics. Teva declined to disclose details. Proteologics...
...programs under a 2005 deal with Proteologics to discover cancer compounds that target ubiquitin ligases. Proteologics...
BioCentury | Dec 28, 2012
Company News

Teva returning preclinical compounds to Proteologics

...it will return rights to three preclinical compounds in development for cancer and inflammation to Proteologics Inc....
...decision to return rights to the three compounds to Proteologics. Teva declined to disclose details. Proteologics...
...programs under a 2005 deal with Proteologics to discover cancer compounds that target ubiquitin ligases. Proteologics...
BioCentury | Dec 10, 2012
Company News

Proteologics board of directors update

Proteologics Inc. (Tel Aviv:PRTL), Orangeburg, N.Y. Business: Infectious, Cancer, Proteomics Appointed: Efri Argaman as chairman WIR Staff cancer Infectious...
BioCentury | Dec 3, 2012
Company News

Proteologics, Teva, XTL deal

...XTL said it acquired 4.6 million (31.35%) of biopharmaceuticals company Proteologics from Teva at NIS1.41 per...
...NIS6.5 million ($1.7 million). XTL said the shares represent the entirety of Teva's stake in Proteologics...
...Proteologics and GlaxoSmithKline plc (LSE:GSK; NYSE:GSK, London, U.K.) partnered to discover drugs to treat cancer. Proteologics Inc....
BioCentury | Jul 21, 2011
Targets & Mechanisms

Celgene skips SKP2

...compounds with improved potency, he noted. In February 2010, GSK entered into a collaboration with Proteologics Inc....
...LSE:GSK; NYSE:GSK), London, U.K. Millennium Pharmaceuticals Inc. (NASDAQ:MLNM), Cambridge, Mass. Progenra Inc. , Malvern, Pa. Proteologics Inc....
BioCentury | Apr 19, 2010
Strategy

Finding cancer flexibility

...for development to treat solid tumors Undisclosed upfront payment, equity investment, milestones, royalties Sep 2008 Proteologics Inc....
BioCentury | Sep 22, 2008
Company News

Proteologics, Teva deal

...programs under a 2005 deal with Proteologics to discover cancer compounds that target ubiquitin ligases. Proteologics...
...also granted Teva an exclusive, worldwide license to an undisclosed discovery program to treat cancer. Proteologics...
...and commercialization. Proteologics is eligible for undisclosed milestones and royalties (see BioCentury, March 9, 2005). Proteologics Inc....
BioCentury | Dec 4, 2006
Company News

Proteologics, Teva deal

...payment was triggered by Proteologics' identification and validation of a ubiquitin ligase as a target. Proteologics Inc....
BioCentury | May 9, 2005
Company News

Proteologics, Teva Pharmaceuticals Industries Ltd. deal

...exchange for milestones and royalties if. Also, TEVA made an undisclosed equity investment in Proteologics. Proteologics Inc....
Items per page:
1 - 10 of 12